[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100338458":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":31,"locations":40,"responsibleParty":63,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":24,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":24,"enrollmentInfo":77,"targetDuration":24,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":24,"overallStatus":43,"whyStopped":24,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Tennessee","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SIR-Spheres Therapy Selection","EXPERIMENTAL","Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET\u002FCT. A final blood draw will take place in conjunction with PET\u002FCT imaging.",[13],"Diagnostic Test: Post therapy PET\u002FCT Imaging",{"label":15,"type":10,"description":16,"interventionNames":17},"TheraSpheres Therapy Selection","Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET\u002FCT. A final blood draw will take place in conjunction with PET\u002FCT imaging.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","Post therapy PET\u002FCT Imaging","whole-body PET\u002FCT following Y90 radioembolization",[9,15],null,[26,29],{"name":27,"affiliation":5,"role":28},"Dustin Osborne, PhD","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":5,"role":28},"Christopher Stephens, MD",[32,36],{"name":27,"role":33,"phone":34,"phoneExt":24,"email":35},"CONTACT","8653058264","dosborne@utmck.edu",{"name":37,"role":33,"phone":38,"phoneExt":24,"email":39},"Shelley Acuff","8653056312","sacuff@utmck.edu",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University of Tennessee Medical Center","RECRUITING","Knoxville","Tennessee","37920","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-83.92074,35.96064,{"lat":53,"lon":52},[56,60,61,62],{"name":57,"role":33,"phone":58,"phoneExt":24,"email":59},"Melissa Weaver","865-305-6181","mweaver@utmck.edu",{"name":37,"role":33,"phone":38,"phoneExt":24,"email":39},{"name":27,"role":28,"phone":24,"phoneExt":24,"email":24},{"name":30,"role":28,"phone":24,"phoneExt":24,"email":24},{"type":64,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[66],{"name":67,"class":68},"Biocompatibles UK Ltd","INDUSTRY","100338458","y90-radioembolization-dose-delivery-and-radiation-exposure-assessment-100338458",false,"NCT03686709","Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment","Inclusion Criteria:\n\n* All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study\n* Must be able to schedule and tolerate additional PET\u002FCT imaging following therapy\n* Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.\n\nExclusion Criteria:\n\n* Patients that are not candidates for Y90 radioembolization therapy\n* Patients that cannot tolerate additional imaging procedures following therapy\n* Patients that cannot tolerate the additional blood draws required for this study\n* Patients whose schedule does not allow them to remain at the hospital for the additional PET\u002FCT imaging study","ALL","18 Years",{"count":78,"type":79},20,"ESTIMATED","INTERVENTIONAL",[82],"NA","The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.",[85,86],"Hepatocellular Carcinoma","Radiation Exposure","2018-09-25",{"date":89,"type":90},"2018-09-27","ACTUAL",{"date":92,"type":90},"2018-06-19",{"date":94,"type":79},"2019-12-31",{"name":5,"class":6},1]